The earnings call reflects a positive sentiment overall, with Pfizer showing strong financial performance, significant advancements in its R&D pipeline, and effective cost management. However, there are some challenges, particularly related to pricing pressures from the IRA Medicare Part D redesign and competitive pressures in the oncology sector.

Company Guidance

During Pfizer's Second Quarter 2025 Earnings Conference Call, the company provided several key metrics and updates on its performance and future guidance. CEO Albert Bourla highlighted Pfizer's strong performance, noting a 10% operational revenue increase to $14.7 billion and raising the adjusted diluted EPS guidance for the full year 2025. The company is actively engaging with policymakers to navigate geopolitical challenges while focusing on R&D productivity, commercial portfolio maximization, and expanding margins. Notable achievements include the progress of Elrexfio in multiple myeloma, with a median overall survival of over two years, and the potential of Sigvotatug Vedotin in non-small cell lung cancer, expected to impact a market projected to reach over $60 billion by 2030. CFO David Denton emphasized strategic financial management, reporting an adjusted EPS of $0.78 and highlighting cost management initiatives contributing to robust operating margins. Pfizer is also preparing for a Phase III start for its C. difficile vaccine candidate and advancing a Phase III program for a Lyme disease vaccine. The company continues to invest in its business, focusing on R&D and strategic partnerships, with a current business development capacity of approximately $13 billion. Overall, Pfizer remains committed to creating long-term shareholder value through disciplined execution and strategic investments.

Strong Year-to-Date Performance and Raised EPS Guidance

Pfizer raised its adjusted diluted EPS guidance for the full year 2025 due to strong year-to-date performance, indicating confidence in its financial outlook.

Significant R&D Advancements

Pfizer highlighted several promising developments in its R&D pipeline, including Elrexfio's notable performance in multiple myeloma and Sigvotatug Vedotin's potential in non-small cell lung cancer.

Strong Growth in Key Products

The Vyndaqel family saw a 21% year-over-year operational growth, and Padcev experienced a 38% operational growth, demonstrating robust demand for key products.

Cost Management and Operating Margins

Pfizer's cost optimization strategies led to an 8% decline in total adjusted operating expenses, contributing to improved operating margins.

Strategic Business Development Initiatives

Pfizer closed an in-licensing agreement with 3SBio, granting exclusive rights to develop and commercialize a promising bispecific antibody.

Pfizer (DE:PFE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:PFE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.61 / -	0.906	―	―	―
Aug 06, 2025	2025 (Q2)	0.50 / 0.67	0.513	30.00% (+0.15)
Apr 29, 2025	2025 (Q1)	0.57 / 0.79	0.701	12.20% (+0.09)
Feb 04, 2025	2024 (Q4)	0.40 / 0.54	0.085	530.00% (+0.45)
Oct 29, 2024	2024 (Q3)	0.52 / 0.91	-0.145	723.53% (+1.05)
Jul 30, 2024	2024 (Q2)	0.39 / 0.51	0.573	-10.45% (-0.06)
May 01, 2024	2024 (Q1)	0.44 / 0.70	1.052	-33.33% (-0.35)
Jan 30, 2024	2023 (Q4)	-0.14 / 0.09	0.975	-91.23% (-0.89)
Oct 31, 2023	2023 (Q3)	-0.07 / -0.15	1.522	-109.55% (-1.67)
Aug 01, 2023	2023 (Q2)	0.49 / 0.57	1.744	-67.16% (-1.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:PFE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	€21.07	€20.64	-1.99%
Apr 29, 2025	€19.53	€20.23	+3.58%
Feb 04, 2025	€24.69	€23.97	-2.89%
Oct 29, 2024	€24.94	€24.58	-1.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.